33 patents
Utility
Glycyrrhetinic acid derivatives for use in treating hyperkalemia
2 Jan 24
Dean Dragoli, Gary Luehr, Tao Chen, Jason Lewis, Michael Leadbetter
Filed: 6 Feb 20
Utility
Compounds and methods for inhibiting phosphate transport
14 Nov 23
Provided are non-NHE3-binding agents having activity as phosphate transport/uptake inhibitors in the gastrointestinal tract, including in the small intestine, methods for their use as therapeutic or prophylactic agents, and related methods of drug discovery.
Dominique Charmot, Jason G. Lewis, Jeffrey W. Jacobs, Ingrid Langsetmo, Christopher Carreras
Filed: 15 Jul 19
Utility
Intestinal Epithelial Cell Cultures
5 Oct 23
Provided are compositions and methods for generating two-dimensional (2D) intestinal epithelial cell cultures for all segments of mouse and human small and large intestines.
Matthew John Siegel
Filed: 7 Apr 23
Utility
Glycyrrhetinic acid derivatives for treating hyperkalemia
26 Sep 23
Gary Luehr, Dean Dragoli, Michael Leadbetter, Tao Chen, Jason Lewis
Filed: 6 Aug 18
Utility
Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
12 Sep 23
Jianhua Chao
Filed: 18 Sep 18
Utility
Methods for Inhibiting Phosphate Transport
7 Sep 23
The present invention relates to methods for lowering serum phosphate in a mammal comprising administering an epithelial phosphate transport inhibitor, such as an NHE3 inhibitor, in combination with a phosphate binder as well as pharmaceutical compositions comprising such epithelial phosphate transport inhibitors and phosphate binders.
Andrew J. King
Filed: 14 Nov 22
Utility
Glycyrrhetinic Acid Derivatives for Treating Hyperkalemia
31 Aug 23
Gary Luehr, Dean Dragoli, Michael Leadbetter, Tao Chen, Jason Lewis
Filed: 24 Jan 23
Utility
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
8 Aug 23
Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
Filed: 7 Apr 21
Utility
Hormone Receptor Modulators for Treating Metabolic Conditions and Disorders
4 May 23
Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
Filed: 6 Jul 22
Utility
Compounds and Methods for Inhibiting Nhe-mediated Antiport In the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders
2 Feb 23
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention.
Dominique Charmot, Marc Navre, Christopher Carreras, Noah Bell, Michael Leadbetter, Jeffrey W. Jacobs
Filed: 1 Apr 22
Utility
Compounds Useful for Treating Gastrointestinal Tract Disorders
29 Sep 22
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention.
Dean DRAGOLI, Irina DOTSENKO, Jason LEWIS
Filed: 21 Dec 21
Utility
Substituted 4-PHENYL Pyridine Compounds As Non-systemic TGR5 Agonists
29 Sep 22
Jason G. Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel
Filed: 25 Feb 21
Utility
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
3 May 22
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention.
Dominique Charmot, Marc Navre, Christopher Carreras, Noah Bell, Michael Robert Leadbetter, Jeffrey W. Jacobs
Filed: 27 Jan 20
Utility
Compounds useful for treating gastrointestinal tract disorders
8 Feb 22
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention.
Dean Dragoli, Irina Dotsenko, Jason Lewis
Filed: 9 Jan 18
Utility
Hormone Receptor Modulators for Treating Metabolic Mutagenic and Fibrotic Conditions and Disorders
9 Dec 21
Jianhua Chao
Filed: 18 Sep 18
Utility
Inhibitors of NHE-mediated antiport
19 Oct 21
Irina Dotsenko, Dean Dragoli, Jason Lewis
Filed: 9 Jan 18
Utility
Isoxazolyl-carbonyloxy AZABICYCLO[3.2.1]OCTANYL Compounds As FXR Activators
30 Sep 21
Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
Filed: 7 Apr 21
Utility
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
17 Aug 21
Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
Filed: 23 Aug 17
Utility
NHE3-BINDING Compounds and Methods for Inhibiting Phosphate Transport
24 Jun 21
Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
Filed: 30 Dec 20
Utility
Glycyrrhetinic Acid Derivatives for Treating Hyperkalemia
3 Jun 21
Gary Luehr, Dean Dragoli, Michael Leadbetter, Tao Chen, Jason Lewis
Filed: 6 Aug 18